Chen Weiying, Chen Feng, Luo Xiaodan, Li Dongmei, Li Hong, Bai Fuhai
Department of Anesthesiology, Xinqiao Hospital of Chongqing, Second Affiliated Hospital of Army Medical University, PLA, Chongqing, China.
Department of Anesthesiology, Xinqiao Hospital of Chongqing, Second Affiliated Hospital of Army Medical University, PLA, Chongqing, China -
Minerva Anestesiol. 2025 May;91(5):430-439. doi: 10.23736/S0375-9393.24.18426-X. Epub 2025 Mar 19.
Propofol, dexmedetomidine, midazolam, and remimazolam are widely used for sedation during bronchoscopy. The purpose of this network meta-analysis was to compare the safety and efficacy of these four sedative drugs for bronchoscopy.
PubMed, Embase, Cochrane Libary, and Wed of Science databases were systematically searched to collect randomized controlled trials (RCTs) of propofol, dexmedetomidine, midazolam, and remimazolam for bronchoscopy from the inception of the database to December 25, 2023. The search strategy we used was (sedative subject terms or sedative free terms) AND (bronchoscopy subject terms or bronchoscopy free terms), without language restrictions. The included studies were randomized controlled trials. Two authors independently searched the databases, selected studies, and extracted data.
Eleven RCTs and 1,076 patients were finally included. The results showed that in terms of hypoxemia, compared to midazolam (RR=0.156, 95% CI [0.031, 0.677]), placebo (RR=1.109, 95% Cl [0.014, 0.977]), propofol (RR=0.112, 95% Cl [0.021, 0.553]), and remimazolam (RR=0.104, 95% Cl [0.012, 0.991]), dexmedetomidine significantly reduced the occurrence of hypoxemia (P<0.05). A surface under the cumulative ranking curve (SUCRA) value indicated a higher ranking of a treatment plan, suggesting that the treatment plan is more advantageous. In terms of hypoxemia, the SUCRA ranking was as follows: dexmedetomidine (98%) > midazolam (57%) > placebo (33%) > remimazolam (32%) > propofol (30%). In terms of arrhythmia, the SUCRA ranking was as follows: dexmedetomidine (89%) > placebo (44%) > remimazolam (42%) > midazolam (40%) > propofol (35%). In terms of bronchoscopy time, the SUCRA ranking was as follows: propofol (68%) > remimazolam (67%) > midazolam (66%) > dexmedetomidine (37%) > placebo (12%).
Compared to midazolam, remimazolam, and propofol, dexmedetomidine significantly reduced the occurrence of hypoxemia and arrhythmia during bronchoscopy. Additionally, bronchoscopy procedures performed under propofol sedation exhibited the shortest operating time.
丙泊酚、右美托咪定、咪达唑仑和瑞马唑仑广泛用于支气管镜检查期间的镇静。本网状荟萃分析的目的是比较这四种镇静药物用于支气管镜检查的安全性和有效性。
系统检索了PubMed、Embase、Cochrane图书馆和科学网数据库,以收集从数据库建立至2023年12月25日有关丙泊酚、右美托咪定、咪达唑仑和瑞马唑仑用于支气管镜检查的随机对照试验(RCT)。我们使用的检索策略是(镇静相关主题词或非主题词)AND(支气管镜检查相关主题词或非主题词),无语言限制。纳入的研究为随机对照试验。两名作者独立检索数据库、选择研究并提取数据。
最终纳入11项RCT和1076例患者。结果显示,在低氧血症方面,与咪达唑仑(RR=0.156,95%CI[0.031,0.677])、安慰剂(RR=1.109,95%CI[0.014,0.977])、丙泊酚(RR=0.112,95%CI[0.021,0.553])和瑞马唑仑(RR=0.104,95%CI[0.012,0.991])相比,右美托咪定显著降低了低氧血症的发生率(P<0.05)。累积排序曲线下面积(SUCRA)值表明治疗方案的排名越高,表明该治疗方案越具优势。在低氧血症方面,SUCRA排名如下:右美托咪定(98%)>咪达唑仑(57%)>安慰剂(33%)>瑞马唑仑(32%)>丙泊酚(30%)。在心律失常方面,SUCRA排名如下:右美托咪定(89%)>安慰剂(44%)>瑞马唑仑(42%)>咪达唑仑(40%)>丙泊酚(35%)。在支气管镜检查时间方面,SUCRA排名如下:丙泊酚(68%)>瑞马唑仑(67%)>咪达唑仑(66%)>右美托咪定(37%)>安慰剂(12%)。
与咪达唑仑、瑞马唑仑和丙泊酚相比,右美托咪定显著降低了支气管镜检查期间低氧血症和心律失常的发生率。此外,丙泊酚镇静下进行的支气管镜检查操作时间最短。